We're probably less restrictive than you think. And then I think the other side of the committee, which I believe still that Chair Powell is in, is looking at a market slowdown in hiring a weak labor market
Mechanistic data Delineating the mechanisms underlying the cardiovascular benefits of GLP-1RA, dual agonists (GLP-1R/GIPR agonists), and tri-agonists (GLP-1R/GIPR/GCGR agonists) is complex, given that their receptors are expressed in various cells across the organism (Hammoud & Drucker 2023)
COMBINATION THERAPY: ARNIs AND SGLT2 INHIBITORS The combination of ARNIs and SGLT2 inhibitors offers a synergistic approach to CMS management by targeting multiple interconnected pathophysiological pathways.59 ARNIs primarily act on the RAAS and natriuretic peptide systems, reducing cardiac stress and remodeling.59 Simultaneously, SGLT2 inhibitors provide metabolic, hemodynamic, and renal protective effects, enhancing cardiovascular and renal outcomes more effectively than monotherapy.60 Emerging evidence suggests that their combination can amplify reductions in heart failure hospitalizations, improve ejection fraction, and slow CKD progression through complementary mechanisms such as enhanced natriuresis, reduced inflammation, and improved myocardial energetics.61 In addition to their cardiovascular and renal effects, ARNIs and SGLT2 inhibitors offer distinct metabolic benefits that may have important implications for CMS management
Many people lose weight without feeling cold, and some experience chills due to individual thermoregulation factors rather than medication efficacy
In studies, some subjects responded to PT-141 in minutes while others took several hours to see the effects
I think many clinicians misunderstand why people lose muscle on GLP1 agonists
